Tuesday, March 10
09:00 - 18:00
Hall D
European Union Funding for Alzheimer Disease
The ADIT Project
FREE REGISTRATION - CLICK HERE
Chairpersons:
A. Rozemuller, ADIT
G.C. Terstappen, ADIT
09:00-09:15 European Union Funding for Alzheimer Disease - The ADIT Project
G. C. Terstappen-ADIT
09:15-09:45 Funding AD Research at the European level
P. Tosetti, European Commission Directorate General for Research
09:45-10:30 The amyloid hypothesis of AD
J. Hardy, UK
10:30-11:00 Drug discovery & development for CNS disorders
M. Pangalos, USA
Break
11:15-12:00 The FP6-funded project ADIT: Employing a systems-based approach for the identification of novel AD targets and chemical
modulators acting on them
G. C. Terstappen-ADIT
12:00-12:30 Towards a patho-pathway of AD
C. Andersen-ADIT
12:30-13:00 Efficient validation of novel AD targets in a drug discovery context
G. Pollio-ADIT
13:00-13:15 Q&A
Lunch
14:15-14:45 Wnt signaling pathway and AD
N. C. Inestrosa, Chile
14:45-15:15 Identification of DKK1 inhibitors for AD treatment
A. Caricasole - ADIT
15:15-15:45 Therapeutic strategies exploiting amyloid-β generation mechanisms
J-N. Octave, Belgium
15:45-16:15 Increased expression of THOP-1 is a neuroprotective response
to Aβ toxicity
J.J.M. Hoozemans, ADIT
Break
16:30-17:00 Aberrant cell cycle re-entry and AD
K. Herrup, USA
17:00-17:30 The poliovirus receptor PVR is associated with AD
A. Tarditi, ADIT
17:30-18:00 Q&A
Tuesday, March 10, 2009
09:00 - 17:40
Corinthia Towers Hotel
MEMOSAD - MEMOLOAD - MEMSTICK
10:30 Welcome & Introduction
Franz Adlkofer, VERUM Foundation
Pathology through Abeta and Abeta oligomers (Chair: Christian Haass)
10:40 Detection of Abeta SDS-stable dimer is a reliable predictor of Alzheimer-type dementia Jessica McDonald, University College Dublin
11:00 Keeping up with beta amyloid; possibilities for the analytical and biological control of the aggregation
Livia Fülöp, University of Szeged
11:20 Pathological Abeta 40/42 ratio facilitates formation of stable neurotoxic forward and backward oligomers
Inna Kuperstein, Flanders Institute for Biotechnology VIB
11:40 Beta-amyloid impairs hippocampal-dependent memory by disrupting CREB-dependent gene transcription
Judit Espana, Universitat Autònoma de Barcelona
12:00 Beta-amyloid-induced changes in synaptic signalling in neocortical neuronal networks
Misha Zilberter, Karolinska Institute
12:20 LUNCH
Tau pathology (Chair: Eva-Maria Mandelkow)
13:20 Tau experimental models: effects of amyloid beta oligomers on Tau pathology Jonathan Brouillette, Université de Lille II
13:40 Reversible tau aggregation and toxicity in a regulatable transgenic mouse model expressing a mutant repeat domain of tau
Astrid Sydow, Max Planck Unit for Structural Molecular Biology
14:00 Investigation of Tau aggregation-mediated toxicity in C. elegans transgenics
Chronis Fatouros, Albert-Ludwigs-Universität Freiburg
14:20 A novel Tau transgenic zebrafish model for drug discovery
Dominik Paquet, Ludwig- Maximilians-Universität München
14:40 Synaptic plasticity and hippocampus-dependent learning and memory in TAU mutant mice
T. Ahmed, Belgium
15:00 COFFEE BREAK
Disease modifying strategies (Chair: Bart De Strooper)
15:20 Aph1B gamma-secretase generates long Abeta peptides, and genetic ablation improves Alzheimer's disease phenotypes without affecting Notch signalling in the mouse
Lutgarde Serneels, Flanders Institute for Biotechnology VIB
15:40 FG-Loop, a novel pharmacological compound, prevents CA1 pyramidal neuron dysfunction and cognitive impairment in Abeta-treated rats
Nicola J. Corbett, The Open University
16:00 Inhibition of JNK enhances hippocampal synaptic plasticity in the rat hippocampus in vivo
Honghong Yang, Ruhr-Universität Bochum
16:20 Mechanisms of calcium-evoked activation of p38 MAPK
Lotta Parviainen, Kuopio University
16:40 Characterization of the role of novel synaptic cell adhesion molecules (CAMs) in learning and memory
Marianne Hald Larsen, Ecole Polytechnique Fédérale de Lausanne
17:00 General discussion (Chair: Luc Buée)
17:30 Awards (Chair: Franz Adlkofer)
17:40 CLOSURE
Wednesday, March 11, 2009
09:00 - 13:00
Hall C
The EU funded AD projects
Presentation of the current AD projects funded under Framework Programme 6 & 7
Chairpersons:
Tobias Hartmann, Germany
Valerie Rolland, Belgium
09:00 – 09:15 Welcome addresses
Tobias Hartmann, LipiDiDiet coordinator, Germany
Valerie Rolland, European Commission, Brussels, Belgium
09:15 – 09:30 ADIT
Georg C. Terstappen, Italy
09:30 – 09:45 NEURO.GSK3: GSK-3 in neuronal plasticity and neurodegeneration: basic mechanisms and pre-clinical assessment
Fred Van Leuven, Belgium
09:45- 10:00 The MEMOSAD Project
Franz Adlkofer, Germany
10:00 – 10:15 EU 7th framework Project MEMOLOAD - neurobiological mechanisms of memory loss in Alzheimer's Disease
Heikki Tanila, Finland
10:15- 10:30 Amyloids-TCCD: Single molecule fluorescence as a tool to study amyloidogenic oligomers
Angel Orte, UK
10:30 – 10:45 NeuroNE: Gene and protein therapy approaches in Parkinson's Disease
Mathias Baehr, Germany
10:45 – 11:00 The MIMOVAX vaccine: a novel AD-treatment strategy targeting truncated Aß40/42 by active immunisation
Markus Mandler, Austria
11:00 – 11:15 The LipiDiDiet Project
Tobias Hartmann, Germany
11:15 – 11:30 AddNeuroMed – a European programme for Alzheimer’s disease biomarker discovery
Simon Lovestone, UK
11:30 – 11:45 The NEUROTAS project: towards an integrated labchipp for the early diagnostic of neurodegenerative disorders
Jörg Kutter, Denmark
11:45 – 12:00 cNEUPRO - Clinical Neuroproteomics of Neurodegenerative Diseases
Jens Wiltfang, Germany
12:00 – 12:15 Beta amyloid oligomers in the early diagnosis of AD and as marker for treatment reponse. The EDAR study
Pieter Jelle Visser, Netherlands
12:15 – 12:30 NEUROSCREEN: differential diagnosis of neurodegenerative diseases – application of real-time immuno-PCR
Willy Zorzi, Belgium
12:30 – 12:45 BrainNet Europe : The European Brain Bank
Hans Kretzschmar, Germany
12:45 – 13:00 NEURAD – international Alzheimer’s Disease PhD graduate school
Thomas Bayer, Germany